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Abstract
Background: The benefit-risk balance of vaccines is regularly debated by the public, but the utility of media
monitoring for regulatory bodies is unclear. A media monitoring study was conducted at the European Medicines
Agency (EMA) concerning human papillomavirus (HPV) vaccines during a European Union (EU) referral procedure
assessing the potential causality of complex regional pain syndrome (CRPS) and postural orthostatic tachycardia
syndrome (POTS) reported to the authorities as suspected adverse reactions.
Methods: To evaluate the utility of media monitoring in real life, prospective real-time monitoring of worldwide
online news was conducted from September to December 2015 with inductive content analysis, generating
‘derived questions’. The evaluation was performed through the validation of the predictive capacity of these
questions against journalists’ queries, review of the EMA’s public statement and feedback from EU regulators.
Results: A total of 4230 news items were identified, containing personal stories, scientific and policy/process-related
topics. Explicit and implicit concerns were identified, including those raised due to lack of knowledge or anticipated
once more information would be published. Fifty derived questions were generated and categorised into 12 themes.
The evaluation demonstrated that providing the media monitoring findings to assessors and communicators resulted
in (1) confirming that public concerns regarding CRPS and POTS would be covered by the assessment; (2) meeting
specific information needs proactively in the public statement; (3) predicting all queries from journalists; and (4) altering
the tone of the public statement with respectful acknowledgement of the health status of patients with CRSP or POTS.
Conclusions: The study demonstrated the potential utility of media monitoring for regulatory bodies to support
communication proactivity and preparedness, intended to support trusted safe and effective vaccine use. Derived
questions seem to be a familiar and effective format for presenting media monitoring results in the scientific-regulatory
environment. It is suggested that media monitoring could form part of regular surveillance for medicines of high
public interest. Future work is recommended to develop efficient monitoring strategies for that purpose.
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Background
The benefit-risk balance of vaccines is frequently debated
in the public domain and in particular in the media. These
debates are linked on the one hand to the high expecta-
tions people have towards vaccines as one of the most
successful health interventions to date and on the other
hand to the phenomenon of vaccine hesitancy [1, 2]. The
media debates have some aspects in common to all
vaccines, but may also be driven by sentiments specific to
certain vaccines [Karafillakis E, Larson H. The benefit of
the doubt: a systematic literature review of perceived risks
of vaccines in European populations. submitted]. Media
attention may increase in cases of information on a new
vaccine, an epidemic of a virus for which there is not yet a
vaccine or the occurrence of a new vaccine-related
concern. Regulatory bodies may be put in the spotlight, as
they are in charge of vaccines licensure, safety surveillance,
continuous benefit-risk assessment and, if needed, risk
minimisation or other regulatory action. They also need to
inform the public about the outcome of their assessments
and provide advice on safe and effective use of vaccines [3].
As the communication process involves not only messa-
ging, but also incorporating information from our sur-
roundings and listening to others, mechanisms for effective
listening need to be established. From the perspective of a
regulatory body, listening should ensure that concerns
expressed in the public domain are addressed in risk
assessments [4], so that information, based on evidence and
plausibility as well as on honesty over uncertainty, can be
provided to the public and addresses their concerns.
Furthermore, listening is an opportunity to collect data
contributing to the body of evidence or its interpretation
for risk assessment, such as data on how medicinal prod-
ucts are used by people. Through applying listening mecha-
nisms, data on information needed by users of medicines
enabling informed choice and safe use of medicines can be
gathered too. In relation to vaccines, listening is a funda-
mental element of a new communication model which
envisions communication as integrating with vaccine safety
assessment and trust-building strategies [5].
Listening mechanisms available to regulatory bodies
include directly interacting with members of the public (e.g.
through working groups, public hearings, information
contact points), conducting or reviewing research (e.g.
surveys) and media monitoring. For the purpose of
optimising communication about vaccines, media moni-
toring was proposed as early as the mid-1990s [6]. Based
on this proposal and other vaccine communication
experiences and research, media monitoring has been
encouraged in the European Union (EU) vaccine pharma-
covigilance guidance addressed to marketing authorisation
holders and regulatory bodies [3]. The most recent media
coverage study in Europe for a specific vaccine, conducted
in Italy in relation to a seasonal influenza vaccine,
recommended that public institutions should engage in
prospective media monitoring [7]. While well-established
medicines agencies conduct general media monitoring
daily, the utility of medicinal product-specific media mon-
itoring for regulatory bodies is as yet unclear.
The case of HPV vaccines
When in July 2015 a EU referral procedure was initiated
for human papillomavirus (HPV) vaccines [8], the
European Medicines Agency (EMA) decided, given fre-
quent media debates about vaccines, to conduct and
evaluate, for the first time, medicinal product-specific
media monitoring to support preparations for communi-
cating with the public about the assessment and outcome
of the referral procedure. The assessment of HPV vaccines
was considered a specifically important test case for media
monitoring, as a public debate with a wide range of topics
about these vaccines had already accompanied their
licensure and launch in 2006. The debate then had been
characterised by celebrating future reduction in mortality
from HPV-related cervical cancer on the one hand, but
also raised a number of concerns on the other, mainly
about long-term effectiveness and benefit [9–14] as well as
safety [9, 11, 13–18]. Beyond benefit and safety, social
concerns had arisen at the time too, speculating that HPV
vaccination would encourage increased or unsafe sexual
activity of the young [13–15].
The media monitoring study was initiated in September
2015 during the EU referral procedure assessing a poten-
tial causal association between HPV vaccines and the
suspected adverse reactions of complex regional pain
syndrome (CRPS) and postural orthostatic tachycardia
syndrome (POTS). Cases of CRPS and POTS symp-
toms occurring after HPV vaccination had been re-
ported to the authorities [8]. The assessment was
carried out by the Pharmacovigilance Risk Assessment
Committee (PRAC), the EMA’s scientific committee
responsible for monitoring and assessing safety issues
for human medicines in the EU and providing recom-
mendations for risk minimisation or other regulatory
action as necessary. The PRAC is composed of
members from each of the 28 EU member states,
Iceland and Norway as well as additional scientific
experts and healthcare professional and patient organ-
isation representatives. Raising a safety issue with a
medicine at EU level through a referral procedure
results in a regulatory decision being implemented in
all member states, Iceland, Norway and Liechtenstein.
The PRAC recommendations on the referral for HPV
vaccines were finalised and published in November
2015. The EMA has a communication department which
prepares communication on all safety-related referral
procedures and responds to queries from the public,
including journalists.
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Methods
Aim and objectives
The aim of this study was to evaluate whether prospect-
ive real-time media monitoring for specific medicinal
products has the potential to enhance communication in
terms of proactivity and preparedness for information
provision to the public, in particular by a regulatory
body.
Therefore, the following objectives were defined:
1. Develop a method for medicinal product-specific
media monitoring in a real-life scenario.
2. Identify, through media monitoring, areas of
concerns, information needs and expectations of the
public in relation to the EU referral procedure
assessment of HPV vaccines and take them into
account when preparing communications.
3. Evaluate the utility of media monitoring to enhance
communication.
It is not the objective of this article to provide infor-
mation on the safety profile of HPV vaccines or to ex-
plain the outcome of the EU referral procedure on HPV
vaccines and CRPS/POTS, as these are presented else-
where [8, 19].
Study period
The study period started on 7 September and lasted
until 23 December 2015, i.e. two months before and
after the PRAC meeting, where the HPV vaccines assess-
ment was scheduled for discussion and finalisation of
the PRAC outcome occurred.
Search strategy
The media monitoring was conducted using Vuelio®, a
media intelligence system which sources media content
from a wide range of news and social media outlets
worldwide in real time [20]. The following search set-
tings were applied to all available online news stories
and blog posts:
– media types: worldwide online health, science, news
and tabloid media, online websites of television
channels and blogs (no restriction was set by e.g.
media type, size of readership or size of country of
origin, as it was considered that some relevant news
would possibly be disseminated only by media with
a small reach or by blogs)
– search terms: the colloquial and technical terms as
well as tradenames: “HPV vaccin*”; “papillomaW/3
vaccin*”; “cervical cancer vaccin*”; “HPV jab”;
“papilloma jab”; “cervical cancer jab”; “Gardasil”;
“Cervarix”; “Silgard” (the asterisk symbol * indicates
that the ending of ‘vaccin’ could vary (e.g. vaccine,
vaccination); ‘W/3’ (or W/2, W/4, W/5, etc.)
indicates the number of words that could be
inserted between two word elements)
– languages: all official EU languages except for
Irish and Maltese, i.e. 22 languages (the search
terms were translated by native speakers at the
EMA).
Daily media screening
Due to the application of a broad search strategy, the
Vuelio system identified a large number of news stories
and blog posts. These articles were first screened daily
by JF for topic relevance, applying the following exclu-
sion criteria, namely if the article:
1. Is about business or financial news only; or
2. Contains no information about HPV vaccines (but
was identified by the system due to the different
meanings of the multilingual search terms in other
languages, in particular of the abbreviation “HPV”).
Articles in languages other than English were initially
screened using Google Translate®, and for those consid-
ered critical, summary translations were provided by
native speakers at the EMA.
Weekly media content analysis
Weekly charts of the global media screening output by
date and by country were prepared by means of the
Vuelio system, and weekly key topic summaries contain-
ing references to articles were created by JF, applying the
following inclusion criteria, namely if the article:
1. Covers a topic about HPV vaccines with higher
weekly media coverage than other topics;
2. Discusses an adverse event following immunisation,
including personal experiences of individuals or the
risk-benefit balance of HPV vaccines;
3. Reports about studies on HPV vaccines;
4. Reports about advocacy or parents’ groups active in
relation to HPV vaccines; or
5. Mentions the EMA, the PRAC or an assessment,
referring to the EU referral procedure for HPV
vaccines.
Based on the key topic summaries, a content analysis
of the included articles was undertaken by PB, resulting
in formulation of considerations for communication
preparations. Content analysis is a qualitative study de-
sign, and as such appropriate for exploring phenomena
not yet well understood. It is an interpretative approach
concerned with understanding the meanings that per-
sons attach to actions, decisions, beliefs and values
within their social world, as well as the mental processes
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persons use to make sense of the world around them
[21]. The considerations for the communication prepa-
rations reflected upon concerns, information needs and
expectations of the public in relation to HPV vaccines
and their benefit-risk assessment by regulatory bodies as
well as experiences and advice blogged by healthcare
providers about the type of questions they are frequently
asked by parents and how they respond. This content
analysis therefore consisted of interpreting the explicit
content as well as connotations and underlying assump-
tions implicit to the content and identifying questions
raised explicitly or implicitly, including those raised due
to lack of knowledge or anticipated to be raised once
more information would be provided in the public
domain. Lack of knowledge in this context refers to
knowledge of scientific nature or about regulatory pro-
cesses beyond the scope of common knowledge.
The charts, the key topic summaries and the consider-
ations were presented in weekly media monitoring
reports.
Presentation and categorisation of media content as
derived questions
A cumulative review of the weekly media content ana-
lyses was performed by PB in the month prior to the
scheduled finalisation of the PRAC assessment for sup-
porting the preparations of the communication for the
EU referral outcome. Identified concerns, information
needs and expectations of the public were used by PB to
derive questions from the media content. These were
worded in an abstract manner, i.e. often differently from
the questions raised explicitly in the media or were
worded anew if the concern had not been presented in
the media as a question at all, but its discussion implied
a question or lack of knowledge which was considered
as important for regulatory bodies to be prepared to an-
swer or even fill with information proactively. The de-
rived questions were written using language with terms
familiar to colleagues in the regulatory and scientific do-
main involved in risk assessment or communication
about the outcome of the assessment. PB grouped the
derived questions into theme-based categories which
had emerged from reviewing the content and organising
these text data. Each category was allocated a high-level
derived question and further sub-questions on specific
aspects.
This approach to content analysis corresponds to an
inductive method, i.e. a method by which concepts for
categorising the content are not defined in advance or
derived from other research but created through the
content analysis itself, and where abstraction is applied
through generating categories. This has been described
as a conceptual and empirical challenge. An inductive
approach is recommended where prior knowledge on
the content or aspects relevant to the purpose of the
content analysis is limited. Instead of relying on pre-
defined categories, this flexible and sensitive approach
allows one to go beyond a simplistic content description
towards a deeper and new understanding of complex
phenomena [22], here the meaning of what has been
expressed explicitly and implicitly in the media. The in-
ductive approach also allowed for creation of categories
specifically relevant to a regulatory body.
Evaluation of utility
For evaluating the utility of medicinal product-specific
media monitoring for regulatory bodies, the following
was undertaken: (1) obtaining feedback in person from
colleagues within the EU regulatory network using the
media monitoring results; (2) reviewing the summary of
PRAC recommendations (PRAC outcome) with a view
on whether and how the derived questions were
addressed; and (3) validating the predictive capacity of
the derived questions by comparing the derived ques-
tions retrospectively with the queries raised by journal-
ists towards the EMA during the study period.
The authors were not involved in the activities of the
PRAC or the EMA communication department during
the time of the referral procedure, had no influence on the
assessment or the drafting of the outcome statement
(other than through providing the results from the media
monitoring) and had no knowledge of the journalist quer-
ies raised during the study period. The authors can there-
fore be considered ‘blinded’ for the purpose of the study.
Results
Media monitoring
A total of 4230 articles (‘news clips’, i.e. news stories
(3737) and blog posts (493)), were collected worldwide
during the monitoring period (after applying the exclusion
criteria). These originated from 2124 media outlets (see
Additional file 1). The highest media coverage for Europe
in terms of absolute numbers of articles was found in
Denmark (626, based on the country allocation in the
Vuelio system), whose authorities received reports for the
suspected adverse reactions of concern at higher rates and
initiated the EU referral procedure [8]. An analysis of in-
tensity of the worldwide coverage for HPV vaccines by
day identified six peaks with more than 100 articles in a
day. The highest peak occurred on 5 November 2015
when the PRAC recommendations on the EU referral pro-
cedure were published by the EMA (Fig. 1). JF related
these peaks to the triggering events identified through the
media screening (Table 1) and compiled all key topics
considered major over time in terms of the volume of
media coverage or the relevance of the topic in rela-
tion to HPV vaccine risks, benefits, marketing author-
isation or immunisation policy decisions (Table 2).
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The media content analysis (after applying the
inclusion criteria) by PB identified patterns over time:
While many debates remained nationally contained,
some topics ‘travelled’, in particular between Scandi-
navian countries and those countries with active par-
ents’ groups, such as Demark, Ireland and the UK.
There was also a change in focus; in particular in
Denmark the debate moved from presenting personal
stories to additionally including scientific and policy-related
points. There were increasingly references to scientific
publications on safety aspects, and overall the debate turned
from questioning vaccine safety as such to doubting the
trustworthiness of the data, the pharmaceutical industry as a
data source and the integrity of the regulatory and other
public health bodies in collecting and assessing data. Some
debates claimed that the EMA and its scientific committees
do not exercise separation between pre- and post-
authorisation decision-making and rely on data provided by
industry rather than requiring data from independent
sources. This led to including in the respective weekly
Fig. 1 Time chart depicting volume of worldwide media coverage from 7 September to 23 December 2015 by day and identifying peaks (generated by the
Vuelio® system)
Table 1 Triggering events of peaks of the worldwide media coverage on HPV vaccines from 7 September to 23 December 2015a
Peak time Peak-triggering event
1st peak, 14 September 2015 Study published by the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM,
the French medicines agency) and the French health insurance, concluding that HPV vaccines do
not increase the risk of autoimmune disorders but suggesting increase of the risk of Guillain-Barré
syndrome [30]
Call by two Republican Party lawmakers in the USA towards schools to oppose mandatory HPV
vaccination of middle school students in Rhode Island [31]
2nd peak, 24 September 2015 Statement of the Catholic bishop in British Columbia, Canada, saying abstinence is the only healthy
choice over HPV vaccination [32]
Announcement in Denmark of the replacement of Gardasil® by Cervarix® in the national HPV
immunisation programme [33]
Report claiming that 1500 girls in Denmark have suspected adverse reactions to HPV vaccines [34]
3rd peak, 22 October 2015 Study published in the journal Epidemiology, Biomarkers and Prevention concluding that a quarter of
doctors in the USA do not strongly endorse HPV vaccination [35]
4th peak, 26 October 2015 Statement of the International Papillomavirus Society (IPVS) endorsing the use of HPV vaccines [36]
Concerns in Denmark on the marketing authorisation holder’s restrictive search strategy on adverse
effects of HPV vaccines [37]
Study published by the US Centers for Disease Control and Prevention (CDC) about low HPV vaccine
uptake among adolescent males in the USA [38]
5th peak, 5 November 2015 Publication by the EMA of the PRAC outcome of the referral procedure, concluding that the evidence
does not support a causal association between HPV vaccines and CRPS or POTS [23]
6th peak, 10 December 2015 Statement by Health Canada referring to a review of international research data suggesting that there
are no new risks associated with Gardasil® and that it can be used safely [39]
aThe references do not provide all news stories or blog posts; they provide the key source as far as identifiable or selected examples of articles
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considerations for communication preparations that regula-
tory bodies should be prepared to answer in detail how they
ensure the legally demanded independence of their work
and manage potential conflicts of interests and how the
pharmaceutical industry is inspected for their compliance
with legal requirements.
Based on the cumulative review of the concerns,
information needs and expectations of the public identified
through the weekly media content analyses, 50 derived ques-
tions were formulated, which could be categorised into 12
themes with a high-level question each (12 questions) and
sub-questions on specific aspects (38 questions) (Table 3).
In addition to the theme categorisation and identify-
ing patterns of flow and focus over time, the media
content analysis allowed for an understanding of some
of the motivations and expectations of parents. The
parents who expressed their opinions in the media con-
sidered the information they had received on vaccine
risks in general as insufficient. Parents who suspected
that their daughters had been harmed by HPV vaccin-
ation mainly wanted to provide case information to the
authorities, obtain support and treatment within the
governmental health insurance as well as remedy the
lack of respect their daughters feel that they experience
in relation to their condition. Some also requested end-
ing the HPV vaccination programme or wanted other
parents to be provided with information about the on-
going EU referral review prior to giving an informed
consent to vaccination. Giving special attention to
respectfully acknowledge the health status of the pa-
tients, regardless of what the outcome of the EU referral
would be, was therefore added to the considerations for
preparing communication.
Utility
The users of the media monitoring results were the
EMA communication department, the PRAC and the
EU member states. Through the media monitoring, the
media office of the EMA communication department
became immediately aware of emerging issues which
needed attention. The weekly media monitoring reports
and the derived questions were circulated within the
EMA and to the PRAC.
(1) Feedback from users of the media monitoring results
PRAC members from those EU member states leading
the EU referral assessment and/or having higher national
media activity or those PRAC members contributing spe-
cial expertise in vaccines or communication (i.e. five PRAC
members) were asked in person for feedback. They noted
that the weekly media monitoring reports enhanced their
communication preparedness for possible questions from
the public they had not envisaged before. Members from
the Scandinavian countries remarked that the reports
helped them to put the media attention at national level in
a broader European and global context. When taking a
specific look at the weekly considerations in early October
2015, the PRAC members leading the assessment con-
firmed that all identified concerns and information gaps re-
lating to CRPS and POTS as voiced by the public would be
covered by the ongoing assessment. It was agreed that the
broader public concerns, such as those about aluminium-
containing adjuvants, had been evaluated in the context of
previous assessments. This provided useful reassurance that
Table 2 Major topics discussed in the media for HPV vaccines
worldwide from 7 September to 23 December 2015a
Topics
Experiences of female adolescents with suspected adverse reactions of
HPV vaccines and beliefs in causal association with HPV vaccines [40]
Number of suspected adverse reaction reports received by the Danish
authorities [34] and concerns in Denmark on the marketing authorisation
holder’s restrictive search strategy on adverse effects of HPV vaccines [37]
Statements from parents claiming that they were not sufficiently
informed about the adverse reaction profile of HPV vaccines before
their decision-making on vaccination [41–43]
Questions about safety and benefits of HPV vaccines [44, 45]
Study on misleading information on HPV vaccines on the Internet [46]
Lack of treatment options for CRPS and POTS [47]
Activities of anti-HPV vaccination groups and opinion leaders [32, 48–53]
Protest by parents and activities by politicians against mandatory HPV
vaccination in Rhode Island, USA [31, 54]
Call by the Irish government for investigations on suspected adverse
reactions with HPV vaccines [42]
Continued suspension of HPV vaccination recommendation by the
Ministry of Health in Japan [55]
USA presidential candidate Donald Trump claiming a causal association
between vaccines and autism [56]
Replacement of Gardasil® by Cervarix® in the national HPV immunisation
programme in Denmark [33]
Support to HPV immunisation programmes [36, 57–59]
Reassuring safety and/or benefit data supporting HPV vaccination
policies [19, 30, 36, 39, 60]
Protection against genital warts by HPV vaccination [61, 62]
Protection against mouth cancer by HPV vaccination and the
importance of immunisation of boys [63]
Low HPV vaccine uptake by female and male adolescents in the USA [38, 64]
Responsibility of physicians for low HPV vaccination rates [35]
Discussion about appropriate HPV vaccination age [65]
Mainly neutral, but also some negative media coverage of the PRAC
recommendation on the EU referral procedure on HPV vaccines [3],
in particular in Denmark and Sweden [66, 67]
Need for further independent studies on the association between HPV
vaccines and CRPS/POTS [68–70]
a The references do not provide all news stories or blog posts; they provide
the key source as far as identifiable or selected examples of articles
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Table 3 Derived questions based on a content analysis of the media coverage for HPV vaccines worldwide from 7 September to
22 October 2015 and categorised by themes
Categories: themes and high-level questions Sub-categories: additional aspect-specific questions
Theme 1 - Assessment scope: 1.0. What is the scope of the
assessment conducted for the EU referral procedure for
HPV vaccines?
1.1. Why does the procedure focus on CRPS and POTS as defined by complex and
difficult-to-apply/ascertain case definitions?
1.2. Why have concerns over autoimmune diseases with HPV vaccines been excluded
from the assessment?
1.3. Why does the evaluation not cover the entire benefit-risk balance of HPV vaccines?
Theme 2 - CRPS and POTS case data: 2.0. What kind of case
reports of CRPS and POTS in association with HPV vaccines
have been reviewed by the authorities, and how?
2.1. How many case reports of CRPS and POTS in association with HPV vaccines have
been received by the authorities, who reported the cases to the authorities and who
are the primary reporters?
2.2. Who confirmed the cases as CRPS and POTS cases?
2.3. How many cases have been received with symptoms of, or similar to those of,
CRPS and POTS but have not met the criteria of the case definitions, how were
these cases reviewed/followed up and how did they have an impact on the
assessment outcome?
2.4. Have all reported cases been followed up by the authorities in order to obtain
more information (to allow for causality assessment)?
2.5. What is the outcome of the analysis of data recorded in EudraVigilance (the adverse
reaction database of the EU regulatory network) requested by parents who have
participated in the EMA meeting with concerned vaccinees and parents to present
their concerns and experiences?
2.6. How were the cases reviewed that had been submitted to the authorities
by the parents’ groups as invited by the EMA?
Theme 3 - Frequency assessment: 3.0. What are the reporting
rates and actual frequencies of CRPS and POTS in association
with HPV vaccines?
3.1. How are these frequencies calculated?
3.2. Where have background frequency data been obtained from, and how confident
can one be in their accuracy?
3.3. What is the likely magnitude of underreporting, and has a sensitivity analysis
been performed for the observed/expected analysis to take underreporting
into account?
3.4. Why are the reporting rates for (any) adverse reactions higher for HPV vaccines
than for other vaccines?
Theme 4 - Other (i.e. not case) CRPS and POTS data: 4.0. What
kind of data has been reviewed for the EU referral procedure
for HPV vaccines in addition to individual case reports?
4.1. What is the nature of these data, and who provided them?
Theme 5 - Assessment of causal association: 5.0. How has the
assessment of CRPS and POTS in possible causal association with
HPV vaccines been performed?
5.1. Have all potential aetiological pathways been investigated, e.g. autoimmune
pathway and impact of female hormones on susceptibility for autoimmune
disease?
5.2. How has causal association been ruled out?
Theme 6 - Overall safety and other safety concerns: 6.0.
What are the overall safety database and safety study results
for HPV vaccines?
6.1. What was the knowledge base at the time of granting the marketing authorisation,
and were the vaccines sufficiently tested at the time?
6.2. How are data assessed for autoimmune diseases, including multiple sclerosis
and Guillain-Barré syndrome?
6.3. How are data assessed for infertility, miscarriage and stillbirth?
Theme 7 - Aluminium: 7.0. What is the knowledge about the
safety of aluminium/AS04 as adjuvant?
7.1. What are the plasma levels for aluminium after vaccination with current HPV
vaccines and with the future Gardasil-9® compared to typical food intake?
7.2. How does the clearance process of aluminium in the human body work?
7.3. Since when has the rate of autism diagnosis been increasing, and is there a
temporal association with the use of aluminium in vaccines?
7.4. What is known about a link between AS04 (aluminium hydroxide +monophosphoryl
lipid A) and autism?
7.5. How similar is AS04 to AS03 (squalene + DL-α-tocopherol + polysorbate 80), which
is the adjuvant in Pandemrix® for which cases of narcolepsy were reported as
suspected adverse reactions?
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no additional data reviews would be necessary to respond
to anticipated questions from the public.
The medical writers of the EMA communication de-
partment stated that they were guided by the derived
questions as to which information items from the as-
sessment to include proactively in the summary of
PRAC recommendations [23], i.e. the public statement
on the PRAC outcome for website publication and dis-
semination to the EU regulatory network, its inter-
national partners, relevant patient and healthcare
professional organisations and journalists (see (2)
below). The derived questions guided these colleagues fur-
ther as to which information to include in the talking
points, prepared for the EMA itself as well as for the au-
thorities in EU member states, to enable prompt provision
of accurate and consistent information in response to ex-
ternal requests, including those from journalists (see (3)
below). The talking points were also used by senior EMA
colleagues to prepare for attending, upon invitation, a
discussion on HPV vaccines at the Danish parliament in
December 2015. The identification of the pattern of the
public debate becoming increasingly focussed on scientific
and policy-related points, particularly in Denmark, was
considered to be especially helpful for these preparations.
(2) Review of the impact of the derived questions on
the summary of PRAC recommendations
The summary of PRAC recommendations [23] showed
that, in addition to reporting upon the assessment
outcome in general, specific information had been
included addressing all categories of derived questions
relating to the assessment of the suspected CRPS/POTS
reported for HPV vaccines, i.e. categories 1 to 5. The
medical writers had selected 7 questions out of 21 (33%),
and addressed them as follows:
– The PRAC reviewed the published research, data
from clinical trials and reports of suspected side
effects from patients and healthcare professionals,
as well as data supplied by Member States; (addresses
derived questions 2.0. and 4.1.).
– The PRAC took into account detailed information
received from a number of patient groups that
also highlighted the impact these syndromes can
have on patients and families (addresses derived
question 2.6.).
– Symptoms of CRPS and POTS may overlap with
other conditions, making diagnosis difficult in
Table 3 Derived questions based on a content analysis of the media coverage for HPV vaccines worldwide from 7 September to
22 October 2015 and categorised by themes (Continued)
Theme 8 - Data trustworthiness: 8.0. Are the data for the EU
referral procedure for HPV vaccines trustworthy?
8.1. What safeguards are there to ensure that marketing authorisation holders do not
manipulate data they submit to the authorities?
8.2. Have data been solicited by the authorities from independent sources?
Theme 9 - Assessment standards and integrity: 9.0. How can it
be demonstrated that signal detection, risk evaluation and
decision-making have been performed to highest standards
during the EU referral procedure for HPV vaccines?
9.1. Have the authorities taken seriously the vaccinated females experiencing
CRPS and POTS?
9.2. How do the authorities manage their conflict of interests?
9.3. Why was the signal of CRPS and POTS with HPV vaccines not identified earlier,
and why was the referral procedure only initiated at the request of Denmark
and not earlier by the EMA?
9.4. Why did the EMA not apply the precautionary principle and suspend the vaccine
while investigations were ongoing?
Theme 10 - Benefit: 10.0. What is the knowledge on the
benefit and effectiveness of HPV vaccines?
10.1. How does the vaccine intervene protectively in the pathway of cancer
development?
10.2. How long is the vaccination effective in vaccinees, and what should vaccinees
do after immunity has decreased?
10.3. What is the potential of strain replacement, and how will this have an impact
on cancer rates?
Theme 11 - Benefit-risk balance: 11.0. What does the
statement ‘the benefits outweigh the risks’ mean?
11.1. Is this statement only applicable at population level or also at the individual
level, and does a positive benefit-risk balance apply to all potential vaccinees
or are there individuals to whom the statement does not apply?
11.2. How are healthcare professionals provided with information so that they can
communicate well with potential vaccinees and parents about the individual
benefit-risk balance?
Theme 12 - Further steps and research: 12.0. What will the impact
of the EU referral outcome be, and will further research be done?
12.1. How do vaccine evaluations by the authorities have an
impact on immunisation policies?
12.2. What kind of further research will be done, and what will be the study objectives?
12.3. How will independence of this research be ensured?
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both the general population and vaccinated
individuals. and The PRAC noted that some
symptoms of CRPS and POTS may overlap with
chronic fatigue syndrome (CFS, also known as
myalgic encephalomyelitis or ME). Many of the
reports considered in the review have features of
CFS and some patients had diagnosis of both POTS
and CFS. Results of a large published study that
showed no link between HPV vaccine and CFS were
therefore particularly relevant. (addresses derived
questions 1.1. and 2.3.).
– …available estimates suggest that in the general
population around 150 girls and young women per
million aged 10 to 19 years may develop CRPS each
year, and at least 150 girls and young women per
million may develop POTS each year. The review
found no evidence that the overall rates of these
syndromes in vaccinated girls were different from
expected rates in these age groups, even taking into
account possible underreporting. (addresses derived
questions 5.0. and 3.3.).
The quotes show that detailed medical and methodo-
logical aspects such as those regarding patient impact,
case ascertainment and adverse event underreporting,
that are usually not included in summaries of PRAC rec-
ommendations, were included in the summary on HPV
vaccines (however it is routine for the EMA to publish
these aspects in the full assessment reports).
With regard to the tone of the summary of PRAC rec-
ommendations, the evaluation identified words intended
to express commitment and diligence towards patients
with CRPS and POTS and to acknowledge the serious-
ness of what they were experiencing. The summary
highlighted that the scientific review was detailed, per-
formed thoroughly and in consultation with leading ex-
perts. It further stressed that CRPS and POTS can
severely affect the quality of life. This kind of wording is
not the routine way of expression of a regulatory body,
and a comparison confirmed that other summaries pub-
lished by the EMA in 2015 were devoid of empathy.
(3) Capacity of derived questions to predict queries
from journalists
The retrospective comparison of the queries from
journalists to the EMA with the derived questions vali-
dated the predictive capacity and utility of media moni-
toring for communication preparations.
At the EMA press briefing about the PRAC outcome
on 5 November 2015, four queries were raised by
journalists [24], which were all predicted by the
derived questions and therefore addressed in the talk-
ing points. This enabled EMA colleagues to provide
well-informed responses promptly at the briefing. The
queries related to themes 2, 3, 4, 5 and 12.
Before and after publication of the PRAC outcome,
the EMA was contacted by journalists, as it is often the
case for EU referral procedures on safety issues. While
the referral procedure for HPV vaccines was ongoing,
journalists often requested the timetable for finalising
the assessment or asked for access to documents or in-
terviews. A total of 16 journalist queries received during
the entire study period contained actual questions, 9 be-
fore and 7 after the publication of the PRAC recommen-
dations on 5 November 2015. These queries all
corresponded with the derived questions (queries before
5 November: 1.0., 1.1., 2.0., 2.3., 3.0., 4.0, 5.0., 9.0, 9.2.,
9.4., 10.0., 10.2. and 10.3., and after 5 November: 1.1.,
2.0., 2.3., 3.0., 3.2., 3.3., 4.0., 7.0., 9.2., 10.0. and 12.0.).
However, in some instances, the level of detail of the
queries from journalists was not predicted. Clarifications
on how referral procedures work in general were also
frequently requested before and after publication of the
PRAC outcome. The EMA responded to all queries from
journalists, whether or not they were included in the
talking points. The EMA’s declaration of interest policy
and actual experts’ declarations had already been made
accessible by the public [25]. For the comparison of the
queries from journalists with the derived questions for
validation purposes, the time period after the publication
of the PRAC recommendations on 5 November was the
relevant one, as the media monitoring results were used
for preparing communication on the PRAC outcome, i.e.
to inform the drafting of the statement on the PRAC
recommendations and the talking points.
Discussion
The article reports on the first time experience of the
EMA with medicinal product-specific media monitoring
and in-depth content analysis. The aim of this study was
to evaluate whether such prospective real-time media
monitoring has the potential to enhance communication
in terms of proactivity and preparedness for information
provision to the public, and the study results contribute
to filling the current knowledge gap as to whether regu-
latory bodies, and other stakeholders in medicines,
should engage in medicinal product-specific media mon-
itoring. To the authors’ knowledge, no other study has
yet been conducted within a regulatory body and evalu-
ated the utility of product-specific media monitoring.
Published studies on vaccines in the media often review
media coverage retrospectively. Here, media monitoring
has been conducted prospectively in real time.
As this study investigated media monitoring for the
purpose of supporting communication proactivity and
preparedness, it was not the objective to quantify
media coverage or obtain a representative picture of
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the public debate. Instead, it was the objective to gain
an understanding of concerns, information needs and
expectations of the public, in the sense of all groups
of the public, since a regulatory body serves all citi-
zens and needs to understand which kind of informa-
tion on scientific evidence and regulatory processes is
missing in the public domain.
Through conducting the study, a method for media
monitoring has been developed, including a new
approach to analysing and presenting media coverage by
translating the media monitoring findings into derived
questions for regulators to consider. With this approach,
concerns, information needs and expectations towards
regulatory bodies that have been discussed in the public
domain explicitly, implied, raised due to a lack of know-
ledge, or anticipated to be raised once more information
has been published, have been expressed in the form of
specific questions in scientific language and with refer-
ence to regulatory policies and procedures. Question for-
mats are familiar to those in the scientific-regulatory
domain and seemed to be an effective way to provide
feedback from the public domain to those in charge of
assessing medicines or defining messages on assessment
outcomes. While media monitoring seeks to understand
relevant mental models (i.e. explanations of someone's
thought process about how something works in the real
world [26]) prevalent in the public domain, the transla-
tion of the media monitoring findings into derived ques-
tions intends to make the findings fit into the thought
processes of the scientific-regulatory domain, whilst
helping to focus communication on specific pieces of in-
formation either missing, or expected, in the public do-
main. Some vaccine safety experts have raised questions
as to whether listening and providing feedback in re-
sponse to unsubstantiated concerns voiced by the public
could risk what has been referred to in the literature as
the ‘social amplification of risk’ [27]. While recognising
this risk, genuinely listening with openness to concerns
voiced by the public and responding honestly and with
transparency is considered essential for building and
sustaining trust [28], a fundamental principle in relation
to matters of public good.
The study used a large data set of worldwide news
stories and blog posts. Although the study was con-
ducted for only one regulatory procedure, it was one of
major importance. However, the study has some limita-
tions in the utility evaluation. Despite media monitoring
findings being widely disseminated via the PRAC to all
EU member states and to the EMA communication de-
partment, feedback was only obtained from those most
closely working on the EU referral procedure itself.
However, more systematic evaluation methods included
reviewing the impact of the media monitoring findings
on the public PRAC outcome statement, and comparing
the derived questions with the queries from journalists,
which revealed their predictive capacity of 100% in terms
of themes. The study did not include a survey or obtain
views directly from young people, parents or healthcare
professionals in the EU. It is assumed that if members of
the public search for information from authorities, they
usually view the websites of the authorities in their own
country rather than the EMA website, given that the
EMA website is mainly visited by professionals in
pharmaceutical industry, regulatory authorities and the
media. Further evaluation could include studying how
the outcome of the EU referral procedure on HPV vac-
cines was reported in the news and social media,
whether public concerns persisted and were discussed in
the light of the assessment by PRAC, or whether jour-
nalists felt satisfied by the information published by the
EMA in terms of scope, format and language. Correlations
between information from regulatory bodies, media cover-
age and vaccination rates among the population would be
interesting for establishing the impact of communication
by regulatory bodies on medicines use behaviours.
In terms of resources, 165 working hours of a commu-
nication specialist (JF) and 75 working hours of a
medicines safety specialist (PB) were used for the media
screening and content analysis in 2015. This equals 0.34
and 0.15, respectively, full-time equivalents per month.
In order to use resources for media monitoring effi-
ciently, the experience from this study suggests that limit-
ing the number of languages monitored to English and to
languages from those countries with high relevant media
coverage could be sufficient, but further work is required
to clarify the most efficient process to support routine
implementation. The use of exclusion terms (e.g. “budget”,
“profit”) to automatically, rather than manually, exclude
articles (e.g. financial news) had been discussed when
setting up the search strategy, but was not implemented
because of concerns around excluding articles about
important policy and trust issues. The study showed that
concerns about profit-driven bias and expectations for
independent data gathering and assessment were indeed
voiced by the public and important to be addressed by
regulatory bodies through transparency of their proce-
dures. In order to investigate if resource efficiency can be
augmented by automated media screening, further work
focussing on developing hierarchical or conditional search
algorithms with increased specificity and without losing
sensitivity is recommended. Now that a potentially workable
method for media content analysis has been developed, fu-
ture media monitoring for other medicinal products could
make efficient use of the available method.
The study results contribute to the Accelerated Devel-
opment of VAccine benefit-risk Collaboration in Europe
(ADVANCE), a private-public consortium aiming to
establish a reliable, valid and tested framework for
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providing rapidly robust data and scientific evidence on
vaccine benefits and risks in Europe. As part of this
framework, ADVANCE is developing recommendations
for communication strategies in relation to vaccine
benefit-risk monitoring [29].
The following principles and actions on communica-
tion are therefore recommended in general for any
stakeholder assessing vaccines (e.g. regulatory and public
health authorities, industry or academia) and for AD-
VANCE in particular:
– Efficient media monitoring should be built into the
process of vaccine benefit-risk monitoring, and
benefit-risk assessment should ensure the provision
of responses to all safety concerns, including those
debated in the public domain.
– Explanations on methods for benefit-risk monitoring
and assessment should be provided in a language
understandable to the public, and should be
developed and ideally be tested with a view to
explaining how the method works and how robust
the results are.
– Given that conflicts of interests are a major concern
voiced by the public, procedures to ensure unbiased
monitoring and assessment as well as, if applicable,
the mechanisms of public-private partnership (PPP)
governance models (as envisaged by ADVANCE
as one option for a future platform for vaccine
benefit-risk monitoring) need to be proactively
communicated to the public.
Conclusions
The study demonstrated the utility of media monitor-
ing for the EMA in the case of the EU referral pro-
cedure for HPV vaccines. The presentation of media
coverage in the newly developed format of a struc-
tured set of derived questions supported scientific
assessors and communicators in focussing on specific
pieces of information, missing or expected in the
public domain, and in enhancing communication pro-
activity and preparedness. More specifically, the study
demonstrated that the derived questions helped the
EMA communication department to proactively en-
rich the public summary statement of PRAC recom-
mendations with medical and methodological aspects.
The derived questions further proved ‘ready-for-use’
by the EMA communication department when draft-
ing the talking points for communication prepared-
ness, enabling prompt responses from the EMA at
the press briefing and to written queries from jour-
nalists. The study demonstrated full predictive cap-
acity regarding the queries from journalists, although
in some instances the level of detail of the questions
was not anticipated. In addition, the findings from
the media monitoring altered the tone of the public
statement with acknowledgement of the health status
of CRSP and POTS patients, in order to meet public
expectations of indicating respect towards patients.
This study seems to be the first on setting up medi-
cinal product-specific media monitoring as a feasible
process within a regulatory body in a real-life sce-
nario and evaluating whether it is useful for improv-
ing its communication. The study suggests that
efficient strategies for medicinal product-specific pro-
spective real-time media monitoring could be part of
safety surveillance for medicines of high public health
impact and/or high public interest and support not
only communication in terms of proactivity and pre-
paredness, but also in relation to transparency and
public participation activities. Overall, medicine safety
and public trust into underlying surveillance systems
could benefit from listening more systematically to
the public, identifying and challenging misleading or
missing information and addressing what different
population groups may want and need to know for
making informed choices and using medicines safely
and effectively.
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